

10 May 2021

Ondexxya (andexanet alfa): Avoid use of andexanet prior to heparinization

Dear Healthcare professional,

Portola Netherlands, B.V., in agreement with the European Medicines Agency and the < *national competent authority* > would like to inform you of the following information regarding Ondexxya (andexanet alfa):

Summary

- **avoid the use of andexanet alfa before heparinization (e.g. during surgery);**
- **andexanet alfa causes unresponsiveness to the anticoagulant effects of heparin;**
- **results of coagulation tests might be misleading when andexanet alfa and heparin are given within a short time of one another. Monitoring of andexanet alfa's effect has not been validated while heparin is active;**
- **use of andexanet alfa for FXa reversal before urgent surgery has not been evaluated.**

Background on the safety concern

Andexanet alfa is indicated for adult patients treated with a direct FXa inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

Off-label use of andexanet alfa to reverse FXa anticoagulation prior to surgery with intended heparin anticoagulation has been reported to cause unresponsiveness to heparin. In-vitro data suggest binding of andexanet alfa to the heparin-anti- thrombin III (ATIII) complex and neutralisation of the anticoagulant effect of heparin.

Extent and duration of the interaction have not been evaluated.

Call for reporting

Ondexxya ▼ is subject to additional monitoring. Healthcare professionals are asked to report any

suspected adverse reactions directly to:

<Details (name, postal address, fax number, website address) on how to access the national spontaneous reporting system >

Company contact point

If you have any questions about this letter or for more information about Ondexxya, please contact Portola Medical Information. Email: info@portolaEU.com or telephone. Phone: 0800 069 8041 or +31 20 225 4560.

Sincerely,